Erlocip 150mg (Erlotinib Tablet) 150mg

Erlocip 150mg is an oral tablet containing 150mg of erlotinib, a medication used in targeted therapy. It belongs to the class of epidermal growth factor receptor inhibitors. Store at room temperature away from moisture and heat. Always follow your healthcare provider's guidance.

Strength

150mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

CIPLA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Erlocip 150mg is primarily used to treat certain types of cancer, including non-small cell lung cancer and pancreatic cancer. It works by slowing or stopping the growth of cancer cells. This medication may be prescribed when other treatments are not suitable. Always consult a healthcare professional for personalized advice.

Side Effects

Erlocip 150mg may help reduce symptoms associated with cancer, such as coughing or breathing difficulties. Some users report improved energy levels and reduced pain over time. Individual responses vary, and effects depend on the condition being treated. Regular monitoring is recommended.

Precautions & Warnings

Keep Erlocip 150mg in its original packaging until ready to use. Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children and pets. Do not use if the packaging is damaged or the tablet appears altered.

Avoid Interactions

Erlocip 150mg may interact with certain medications, including strong CYP3A4 inhibitors or inducers. Avoid grapefruit products while taking this medication. Discuss all current medications with your healthcare provider before starting erlotinib. Alcohol use should be limited or avoided.

References

Frequently Asked Questions

Erlocip 150mg is used in targeted therapy for certain cancers like non-small cell lung cancer and pancreatic cancer.

Store Erlocip 150mg at room temperature, away from moisture, heat, and direct sunlight.

Consult your healthcare provider before combining Erlocip 150mg with other drugs, as interactions may occur.

Avoid grapefruit products and limit alcohol use while taking Erlocip 150mg.

Erlocip 150mg should only be used under medical supervision, as individual health conditions may affect its safety.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.